Juno Therapeutics Inc (NASDAQ:JUNO) was downgraded by research analysts at SunTrust Banks Inc. from a “buy” rating to a “hold” rating in a report released on Friday. They currently have a $25.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $48.00. SunTrust Banks Inc.’s target price suggests a potential upside of 10.82% from the company’s previous close.

A number of other brokerages have also recently issued reports on JUNO. Vetr cut shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price objective for the company. in a report on Tuesday, August 16th. Standpoint Research began coverage on shares of Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 price objective for the company. BTIG Research began coverage on shares of Juno Therapeutics in a report on Tuesday, August 30th. They set a “sell” rating and a $23.00 price objective for the company. FBR & Co set a $61.00 price objective on shares of Juno Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Maxim Group reduced their price objective on shares of Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating for the company in a report on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $41.47.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) opened at 22.56 on Friday. The company has a 50-day moving average of $27.75 and a 200-day moving average of $33.02. Juno Therapeutics has a 52 week low of $19.41 and a 52 week high of $57.82. The firm’s market cap is $2.31 billion.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $20.80 million for the quarter, compared to analyst estimates of $10.98 million. The company’s revenue for the quarter was up 1200.0% on a year-over-year basis. During the same period last year, the firm earned ($0.26) EPS. Equities research analysts forecast that Juno Therapeutics will post ($2.54) earnings per share for the current fiscal year.

In other news, EVP Robert Azelby sold 12,921 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the sale, the executive vice president now owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Hans Edgar Bishop sold 23,042 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $30.06, for a total transaction of $692,642.52. Following the completion of the sale, the chief executive officer now directly owns 2,541,151 shares in the company, valued at approximately $76,386,999.06. The disclosure for this sale can be found here.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Juno Therapeutics by 14.8% in the second quarter. Vanguard Group Inc. now owns 5,471,650 shares of the biopharmaceutical company’s stock valued at $210,331,000 after buying an additional 707,140 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Juno Therapeutics by 40.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,663,180 shares of the biopharmaceutical company’s stock valued at $63,933,000 after buying an additional 475,709 shares during the period. Lord Abbett & CO. LLC raised its stake in Juno Therapeutics by 222.9% in the second quarter. Lord Abbett & CO. LLC now owns 688,876 shares of the biopharmaceutical company’s stock valued at $26,480,000 after buying an additional 475,553 shares during the period. BlackRock Fund Advisors raised its stake in Juno Therapeutics by 29.5% in the second quarter. BlackRock Fund Advisors now owns 1,964,403 shares of the biopharmaceutical company’s stock valued at $75,512,000 after buying an additional 446,978 shares during the period. Finally, State Street Corp raised its stake in Juno Therapeutics by 36.1% in the second quarter. State Street Corp now owns 1,658,792 shares of the biopharmaceutical company’s stock valued at $63,764,000 after buying an additional 440,324 shares during the period.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/25/juno-therapeutics-inc-juno-rating-lowered-to-hold-at-suntrust-banks-inc.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.